DOA
UTHR icon

D'Orazio & Associates’s United Therapeutics UTHR Stock Holding History

D'Orazio & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7
Closed -$1K – 676
2021
Q3 		$1K Buy
+7
New +$1.38K ﹤0.01% 756

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

D'Orazio & Associates's UTHR Position: Q4 2021 in Review

D'Orazio & Associates sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 7 shares — an estimated $1K sold.

D'Orazio & Associates first reported a position in UTHR in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • D'Orazio & Associates reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
  • D'Orazio & Associates sold 7 United Therapeutics shares in Q4 2021, an estimated $1K.
  • D'Orazio & Associates first reported a position in United Therapeutics in Q3 2021 and held it in 1 quarter.
  • D'Orazio & Associates's United Therapeutics position peaked at $1K in Q3 2021.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.